Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENERGIZE: Sodium Zirconium Cyclosilicate for Hyperkalemia
NCT03337477Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2018
- Primary completion
- Dec 2018
- Modality
- DNA Intercalators/Alkylators
- Countries
- 4
01
Overview
A Phase 2 trial of sodium zirconium cyclosilicate in hyperkalemia, sponsored by AstraZeneca. Started Feb 2018; status: completed.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT03337477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03337477.